TSTiffany M. Styles

Tiffany M. Styles

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tiffany M. Styles has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identifying correlates of viral rebound timing and viral control in SHIV-infected infant macaques after ART interruption

    by Veronica Obregon-Perko, Achal Awasthi, Richard Barfield, Stella J. Berendam, Bhrugu Yagnik, Tiffany Styles, Greg Tharp, Prachi M. Gupta, Gloria Mensah, Margaret Neja, et al.

    Evaluation of HIV cure strategies requires antiretroviral therapy (ART) interruption, but ethical and clinical considerations make this difficult in children. Here, we used a pediatric preclinical model of simian-HIV (SHIV) infection to uncover features associated with time to viral rebound (TTR) and posttreatment control (PTC) of rebound viremia after ART interruption to inform the design of studies testing cure interventions. We assessed 141 variables in SHIV-infected infant rhesus macaques in three staggered ART initiation groups and during subsequent analytical treatment interruption (ATI). Viral rebound occurred in 25 of 30 macaques within 7 to 98 days of ATI, with TTR delayed in the early ART group compared with the intermediate and late ART groups. Peak plasma viral load pre-ART was the most important correlate of TTR, with increased model performance through the successive inclusion of six additional viral and immune variables. The odds of PTC were reduced with higher SHIV RNA in rectal CD4 + T cells pre-ATI; conversely, higher frequencies of Ki67 + effector memory CD8 + T cells in lymph nodes increased the likelihood of PTC. RNA sequencing of CD4 + T cells pre-ATI revealed a down-regulated metabolic and immune gene signature in macaques with PTC. Analysis of the early ART group alone implicated transforming growth factor–β signaling genes in lack of viral rebound off ART. This comprehensive investigation reveals major determinants of viral rebound dynamics after ART interruption that should be validated and explored as potential biomarkers to screen children with HIV being considered for ATI.


  • A clade C HIV-1 vaccine protects against heterologous SHIV infection by modulating IgG glycosylation and T helper response in macaques

    by Anusmita Sahoo, Andrew T. Jones, Narayanaiah Cheedarla, Sailaja Gangadhara, Vicky Roy, Tiffany M. Styles, Ayalnesh Shiferaw, Korey L. Walter, LaTonya D. Williams, Xiaoying Shen, et al.

    The rising global HIV-1 burden urgently requires vaccines capable of providing heterologous protection. Here, we developed a clade C HIV-1 vaccine consisting of priming with modified vaccinia Ankara (MVA) and boosting with cyclically permuted trimeric gp120 (CycP-gp120) protein, delivered either orally using a needle-free injector or through parenteral injection. We tested protective efficacy of the vaccine against intrarectal challenges with a pathogenic heterologous clade C SHIV infection in rhesus macaques. Both routes of vaccination induced a strong envelope-specific IgG in serum and rectal secretions directed against V1V2 scaffolds from a global panel of viruses with polyfunctional activities. Envelope-specific IgG showed lower fucosylation compared with total IgG at baseline, and most of the vaccine-induced proliferating blood CD4 + T cells did not express CCR5 and α4β7, markers associated with HIV target cells. After SHIV challenge, both routes of vaccination conferred significant and equivalent protection, with 40% of animals remaining uninfected at the end of six weekly repeated challenges with an estimated efficacy of 68% per exposure. Induction of envelope-specific IgG correlated positively with G1FB glycosylation, and G2S2F glycosylation correlated negatively with protection. Vaccine-induced TNF-α + IFN-γ + CD8 + T cells and TNF-α + CD4 + T cells expressing low levels of CCR5 in the rectum at prechallenge were associated with decreased risk of SHIV acquisition. These results demonstrate that the clade C MVA/CycP-gp120 vaccine provides heterologous protection against a tier2 SHIV rectal challenge by inducing a polyfunctional antibody response with distinct Fc glycosylation profile, as well as cytotoxic CD8 T cell response and CCR5-negative T helper response in the rectum.


  • Open Access

    Lymph node CXCR5+ NK cells associate with control of chronic SHIV infection

    by Sheikh Abdul Rahman, James M. Billingsley, Ashish Arunkumar Sharma, Tiffany M. Styles, Sakthivel Govindaraj, Uma Shanmugasundaram, Hemalatha Babu, Susan Pereira Riberio, Syed A. Ali, Gregory K. Tharp, et al.

    The persistence of virally infected cells as reservoirs despite effective antiretroviral therapy is a major barrier to an HIV/SIV cure. These reservoirs are predominately contained within cells present in the B cell follicles (BCFs) of secondary lymphoid tissues, a site that is characteristically difficult for most cytolytic antiviral effector cells to penetrate. Here, we identified a population of NK cells in macaque lymph nodes that expressed BCF-homing receptor CXCR5 and accumulated within BCFs during chronic SHIV infection. These CXCR5 + follicular NK cells exhibited an activated phenotype coupled with heightened effector functions and a unique transcriptome characterized by elevated expression of cytolytic mediators (e.g., perforin and granzymes, LAMP-1). CXCR5 + NK cells exhibited high expression of FcγRIIa and FcγRIIIa, suggesting a potential for elevated antibody-dependent effector functionality. Consistently, accumulation of CXCR5 + NK cells showed a strong inverse association with plasma viral load and the frequency of germinal center follicular Th cells that comprise a significant fraction of the viral reservoir. Moreover, CXCR5 + NK cells showed increased expression of transcripts associated with IL-12 and IL-15 signaling compared with the CXCR5 – subset. Indeed, in vitro treatment with IL-12 and IL-15 enhanced the proliferation of CXCR5 + granzyme B + NK cells. Our findings suggest that follicular homing NK cells might be important in immune control of chronic SHIV infection, and this may have important implications for HIV cure strategies.


  • Open Access

    Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies

    by Anusmita Sahoo, Edgar A. Hodge, Celia C. LaBranche, Tiffany M. Styles, Xiaoying Shen, Narayanaiah Cheedarla, Ayalnesh Shiferaw, Gabriel Ozorowski, Wen-Hsin Lee, Andrew B. Ward, et al.


  • Open Access

    Correlates of Protection Against SIVmac251 Infection in Rhesus Macaques Immunized With Chimpanzee-Derived Adenovirus Vectors

    by Steven Tuyishime, Larissa H. Haut, Raj K. Kurupati, James M. Billingsley, Diane Carnathan, Sailaja Gangahara, Tiffany M. Styles, ZhiQuan Xiang, Yan Li, Malte Zopfs, et al.